Imexpharm Corporation (HOSE:IMP)

Market Cap	8.25T
Revenue (ttm)	2.45T
Net Income (ttm)	333.14B
Shares Out	154.01M
EPS (ttm)	2,163.10
PE Ratio	24.78
Forward PE	24.50
Dividend	500.00 (0.92%)
Ex-Dividend Date	Jun 9, 2025

Volume	61,372
Average Volume	57,083
Open	54,900
Previous Close	54,500
Day's Range	53,600 - 54,900
52-Week Range	36,100 - 56,500
Beta	0.72
RSI	65.84
Earnings Date	Jan 16, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. The company was founded in 1997 and is headquartered in Cao Lãnh, Vietnam.

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.